



## **Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022**

**VANCOUVER, BC, November 23, 2022 /CNW/** – Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time.

Rakovina invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive on-line presentation at the Emerging Growth Conference.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s management.

Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions with conference participants.

**Rakovina Therapeutics will be presenting at 10:15AM Eastern time for 30 minutes.**

Please register here to ensure you are able to attend the conference and receive any updates that are released.

[https://goto.webcasts.com/starthere.jsp?ei=1575088&tp\\_key=b1fead5049&sti=rkv](https://goto.webcasts.com/starthere.jsp?ei=1575088&tp_key=b1fead5049&sti=rkv)

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com

### **About the Emerging Growth Conference**

The Emerging Growth conference provides an efficient platform for public companies to present and communicate their new products, services and other announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

### **About Rakovina Therapeutics Inc.**

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at [www.rakovinatherapeutics.com](http://www.rakovinatherapeutics.com).

## **Additional Information**

*The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.*

### **Notice regarding forward-looking statements:**

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at [www.sedar.com](http://www.sedar.com).

### **Contact:**

#### **Rakovina Therapeutics Inc.**

David Hyman

Chief Financial Officer

Email: [info@rakovinatherapeutics.com](mailto:info@rakovinatherapeutics.com)

#### **Investor Relations Contact**

[IR@rakovinatherapeutics.com](mailto:IR@rakovinatherapeutics.com)

#### **Media Contact**

[MEDIA@rakovinatherapeutics.com](mailto:MEDIA@rakovinatherapeutics.com)